Thermal Imaging in Liver Disease.

Thermal Imaging of the Peripheral Vasculature in Liver Disease.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03279419

Enrollment

Registered

2017-09-12

Start date

2019-09-01

Completion date

2019-12-01

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Diseases

Brief summary

This is a feasibility study, to assess if thermal imaging and/or near infrared imaging will be useful in identifying changes in the peripheral circulation in patients with different stages of liver disease. The aim of this study is to use new and advanced thermal imaging techniques to identify changes in the peripheral circulation and hand temperature in patients with liver disease. These changes could be used as a non-invasive marker of the severity and progression of liver disease. Thermal imaging will also be used to assess the changes in the peripheral vasculature with the use of terlipressin, a drug used as treatment for specific complications of liver disease. Patients with acute or chronic liver disease from any aetiology will be recruited, along with patients without liver disease as healthy controls. Patients with disease or on drugs known to affect the peripheral vasculature will be excluded. All studies will be performed in a ward setting in the Royal Infirmary of Edinburgh. The subjects will be required for up to three sessions, each lasting 30 minutes. The session will involve static thermal images being taken, and video images of the hands warming up after being cooled for 30 seconds in water at a temperature of 7 degrees Celsius. If the patient is receiving terlipressin therapy, static images will be taken before, during and after terlipressin therapy.

Interventions

DIAGNOSTIC_TESTThermal imaging

Use of thermal imaging camera to capture images of peripheral vasculature (hands).

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* diagnosis of chronic liver disease (any stage) * diagnosis of acute liver disease (any aetiology)

Exclusion criteria

* on drugs known to affect peripheral circulation * conditions known to affect peripheral circulation e.g. Raynauds

Design outcomes

Primary

Measure	Time frame
Changes in peripheral vasculature as assessed by thermal imaging	2 years

Secondary

Measure	Time frame
Changes in peripheral vasculature in response to terlipressin therapy.	2 years

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026